The vast majority (86.8%) of trials were open-label, while only 13.2% used blinding.
绝大部分的临床试验（86.8%）属于开放性的，只有13.2%的临床试验采用了盲法设计；
2
Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.
紫杉醇与S-1作为转移性乳腺癌的一线化疗（选择BC）：一项开放标签、非劣效性、随机3期试验。
3
During a blinded period, patients received active or sham stimulation, followed by an open-label phase in which all the patients received active stimulation.